abrdn Life Sciences director buys 527 HQL shares
abrdn Life Sciences Investors director Chris LaVictoire Mahai purchased 527 shares of Common Stock on 2026-07-16 in an open-market or private transaction at $19.92 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
abrdn Life Sciences Investors director Chris LaVictoire Mahai purchased 527 shares of Common Stock on 2026-07-16 in an open-market or private transaction at $19.92 per share. After this trade, Mahai directly owns 527 shares of HQL. The filing indicates the transaction was not under a Rule 10b5-1 trading plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 527 | $19.92 | $10K |
Key Figures
Key Terms
Rule 10b5-1 trading plan financial
open market or private transaction financial
direct ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did HQL report for Chris LaVictoire Mahai?
What are Chris LaVictoire Mahai’s HQL holdings after this Form 4 trade?
Is Mahai’s HQL transaction classified as a buy or sell on the Form 4?
Is Mahai’s ownership in HQL direct or indirect after this transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.